Nightingale S, Cal S, Peterson DM, Loss S, Watson D, Manzone C, Baker J; International Conference on AIDS.
Int Conf AIDS. 1991 Jun 16-21; 7: 251 (abstract no. W.B.2279).
University of Texas Southwestern Medical School, Dallas, TX, USA
OBJECTIVE: To compare the incidence of disseminated fungal infections in HIV-positive patients with CD4 counts less than 68/mm3 before and after March 1, 1990, when routine prophylaxis in such patients with fluconazole 100 mg/day was instituted in our AIDS clinic. METHODS: Two hundred eighty-nine patients were treated for a total of 106 patient-years. An historical control group of 366 patients with CD4 counts less than 68/mm3 seen in our clinic between October 1, 1988, and February 28, 1990 was identified. The control cohort was followed for 168 patient-years. No apparent differences between the two cohorts except dates of observation and prophylactic fungal therapy were identified. Both cohorts were followed with monthly Isolator-10 (DuPont) blood cultures. Survival without disseminated fungal infection in the two groups was compared using the SAS procedure Lifetest. RESULTS: One infection, disseminated cryptococcosis, developed in the treated group. Twenty infections (14 cryptococcosis, 6 histoplasmosis) developed in the historical control group (p less than .05). The one treatment failure occurred 3 weeks after prophylaxis was begun. CONCLUSION: In comparison to historic controls, oral fluconazole 100 mg per day significantly reduced the incidence of systemic fungal infections in HIV-positive patients with CD4 counts less than 68/mm3.
Publication Types:
Keywords:
- Acquired Immunodeficiency Syndrome
- Antiretroviral Therapy, Highly Active
- Cryptococcosis
- Fluconazole
- HIV Seropositivity
- Histoplasmosis
- Humans
- Mycoses
- drug therapy
- prevention & control
- therapy
Other ID:
UI: 102192883
From Meeting Abstracts